ePrints

B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis

Lookup NU author(s): Professor Jaap Van Laar

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.

Publication metadata

Author(s): van Laar JM

Publication type: Editorial

Publication status: Published

Journal: Arthritis Research & Therapy

Year: 2010

Volume: 12

Issue: 2

Pages: -

Print publication date: 01/01/2010

ISSN (print): 1478-6354

ISSN (electronic): 1478-6362

Publisher: BioMed Central Ltd.

Share